Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany; Integrated Research Training Group (IRTG) Medical Epigenetics, Collaborative Research Centre 992, Freiburg, Germany; Faculty of Biology, Albert-Ludwigs-University of Freiburg, Germany.
Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Curr Opin Immunol. 2021 Oct;72:176-185. doi: 10.1016/j.coi.2021.05.010. Epub 2021 Jun 19.
'There is no gene for fate' (citation from the movie 'GATTACA') - and there is no gene for CVID. Common Variable ImmunoDeficiency (CVID) is the most prevalent primary immunodeficiency in humans. CVID is characterized by an increased susceptibility to infections, hypogammaglobulinemia, reduced switched memory B cell numbers in peripheral blood and a defective response to vaccination, often complicated by autoimmune and autoinflammatory conditions. However, as soon as a genetic diagnosis has been made in a patient with CVID, the diagnosis must be changed to the respective genetic cause (www.esid.org). Therefore, there are genetic causes for primary antibody deficiencies, but not for CVID. Primary antibody deficiencies (PADs) are a heterogeneous group of disorders. Several attempts have been made to gain further insights into the pathogenesis of PAD, using unbiased approaches such as whole exome or genome sequencing. Today, in just about 35% of cases with PAD, monogenic mutations (including those in the gene TNFRSF13B) can be identified in a set of 68 genes [1]. These mutations occur either sporadically or are inherited and do explain an often complex phenotype. In our review, we not only discuss gene defects identified in PAD patients previously diagnosed with CVID and/or CVID-like disorders such as IKZF1, CTNNBL1, TNFSF13 and BACH2, but also genetic defects which were initially described in non-CVID patients but have later also been observed in patients with PAD such as PLCG2, PIK3CG, PMS2, RNF31, KMT2D, STAT3. We also included interesting genetic defects in which the pathophysiology suggests a close relation to other known defects of the adaptive immune response, such as DEF6, SAMD9 and SAMD9L, and hence a CVID-like phenotype may be observed in the future. However, alternative mechanisms most likely add to the development of an antibody-deficient phenotype, such as polygenic origins, epigenetic changes, and/or environmental factors.
“命运没有基因”(引自电影《千钧一发》)——而普通变异型免疫缺陷(CVID)也没有基因。普通变异型免疫缺陷(CVID)是人类最常见的原发性免疫缺陷。CVID 的特征是易感染、低丙种球蛋白血症、外周血中成熟记忆 B 细胞数量减少以及疫苗接种反应缺陷,常伴有自身免疫和自身炎症性疾病。然而,一旦在 CVID 患者中做出基因诊断,就必须将诊断更改为相应的遗传原因(www.esid.org)。因此,原发性抗体缺陷有遗传原因,但 CVID 没有。原发性抗体缺陷(PAD)是一组异质性疾病。人们已经尝试使用全外显子或基因组测序等无偏方法来进一步深入了解 PAD 的发病机制。如今,在大约 35%的 PAD 病例中,可以在一组 68 个基因中发现单基因突变(包括 TNFRSF13B 基因中的突变)[1]。这些突变要么是偶然发生的,要么是遗传的,确实可以解释一种通常很复杂的表型。在我们的综述中,我们不仅讨论了先前被诊断为 CVID 和/或 CVID 样疾病(如 IKZF1、CTNNBL1、TNFSF13 和 BACH2)的 CVID 患者中发现的基因缺陷,还讨论了最初在非 CVID 患者中描述但后来也在 PAD 患者中观察到的基因缺陷,如 PLCG2、PIK3CG、PMS2、RNF31、KMT2D 和 STAT3。我们还包括了一些有趣的基因缺陷,其病理生理学表明与其他已知的适应性免疫反应缺陷密切相关,如 DEF6、SAMD9 和 SAMD9L,因此在未来可能会观察到 CVID 样表型。然而,多基因起源、表观遗传变化和/或环境因素等其他机制很可能会导致抗体缺陷表型的发展。